PTHrP analogue (anabolic)
Abaloparatide
Brand names: Eladynos
Adult dose
Dose: 80 micrograms
Route: Subcutaneous
Frequency: Once daily for max 18 months
Clinical pearls
- For postmenopausal osteoporosis at high fracture risk
- Follow with antiresorptive on completion
Contraindications
- Pre-existing hypercalcaemia
- Severe renal impairment
- Prior skeletal radiotherapy
- Bone metastases
- Paget disease
Side effects
- Hypercalcaemia
- Palpitations
- Dizziness
- Nausea
- Injection site reaction
Interactions
- Cardiac glycosides (monitor)
- Loop diuretics
Monitoring
- Serum and urinary calcium
- BMD
- BP/HR
Reference: BNF; NICE TA991; SmPC Eladynos. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016